Medtronic Wins Full Reimbursement Codes as Wall Street Splits on the Road Ahead

AMA grants Medtronic Category-I CPT codes for Altaviva and Symplicity Spyral, effective January 2028, as MiniMed spinoff offer closes October 9.

Medtronic has secured a pair of Category-I CPT codes from the American Medical Association, a regulatory green light that stands to shape the commercial trajectory of two of its newer therapy platforms. The billing designations cover Altaviva, an implantable tibial neuromodulation device, and the Symplicity Spyral system for renal denervation. Both replace the provisional Category-III codes the company had been operating under and formally take effect in January 2028.

The distinction matters well beyond paperwork. Category-III codes are reserved for procedures still considered experimental, whereas full Category-I status opens the door to standardized reimbursement from payers. For Medtronic, that translates into a clearer path for physicians and hospitals once the two systems move into routine clinical use.

A Spinoff With a Sweetener Attached

While the reimbursement news landed Thursday, Medtronic's broader portfolio overhaul has been running on a separate track. The separation of its diabetes unit, MiniMed, was set in motion roughly three weeks ago and has coincided with a 2.2% decline in the share price since then. As part of the transaction, the company is offering up to 225,361,295 newly issued MiniMed shares in exchange for Medtronic common stock.

The terms carry an incentive for participating investors: for every $100 worth of Medtronic shares tendered, holders would receive MiniMed stock valued at approximately $107.53. The final exchange ratio will hinge on the two stocks' market prices before the offer is scheduled to close on October 9, 2026.

Analysts See the Stock Two Ways

Opinion on Wall Street remains genuinely divided. RBC Capital Markets' Kendall Au reiterated a "Buy" rating on Thursday with a $118 price target. Piper Sandler's Matthew O'Brien took a more cautious line, assigning a "Hold" on September 28 with an $85 target. A third voice entered the fray over the weekend, when Wall Street Zen upgraded the shares from "Hold" to "Buy," citing the company's recent quarterly results and the appeal of defensive healthcare names in the current market climate.

The Operating Story Behind the Optimism

Those quarterly numbers give the bulls something to work with. Medtronic closed fiscal 2026 with revenue growth of 8.4% — its strongest in a decade — and carried that momentum into the first quarter of fiscal 2027, when sales climbed nearly 14%. The report, released September 1, showed revenue of $9.76 billion and adjusted earnings per share of $1.45, both ahead of expectations. Management is guiding for full-year fiscal 2027 EPS of $5.94 to $6.00.

New technologies feature prominently in the growth plan, among them the Hugo surgical robotics platform. The sector's defensive characteristics add another layer of support: with interest rates still elevated and bond yields choppy, medical procedures tend to hold up better than discretionary spending, giving device makers a degree of insulation from the economic cycle.

Restructuring on the Cardiac Side

Medtronic is simultaneously tightening its internal structure. According to media reports, the company plans to reorganize its cardiovascular business into two separate units. As part of that effort, its Santa Rosa, California facility — a site with roots in a 1998 acquisition — is slated to close within two years, with roughly 370 positions expected to be cut there by spring 2027.

A Dividend Streak That Keeps Running

For income-focused investors, the payout record remains a fixture. Medtronic has raised its dividend for 49 consecutive years. The next quarterly distribution, payable October 16 to shareholders of record as of September 25, comes in at $0.72 per share, equivalent to an annualized $2.88.

In European trading, the stock finished the prior session at EUR 76.72, a modest daily decline of 0.3%, leaving the company with a market capitalization of EUR 98.13 billion.